The present invention also provides any one of the embodiments disclosed below and indicated with the numbers 1 to 35.

1. An antibody having the ability of binding to GT468 and mediating killing and/or inhibition of one or more activities of cells expressing GT468.

2. The antibody of claim 1 wherein said activity is selected from the group consisting of cell motility, cell migration, invasion of cells and cell proliferation.

3. The antibody of claim 1 wherein said activity is cell proliferation.

4. The antibody of any one of claims 1-3 wherein said killing and/or inhibition of one or more activities of cells is induced by binding of said antibody to GT468 expressed by said cells.

5. The antibody of any one of claims 1-4 wherein said killing and/or inhibition of one or more activities of cells is induced by binding of said antibody to the extracellular domain of GT468 expressed by said cells.

6. The antibody of any one of claims 1-5 wherein said killing and/or inhibition of one or more activities is not induced by binding of said antibody to non-cancerous GT468 expressing cells.

7. The antibody of any one of claims 1-6 wherein said cells expressing GT468 are cancer cells.

8. The antibody of claim 7 wherein the cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian and hepatocellular cancer cells.

9. The antibody of any one of claims 1-8 which mediates said killing of cells by inducing complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent cellular cytotoxicity (ADCC) mediated lysis, apoptosis, homotypic adhesion, and/or phagocytosis.

10. The antibody of any one of claims 1-9 which mediates said killing of cells by inducing CDC mediated lysis and/or ADCC mediated lysis.

11. The antibody of any one of claims 1-10 which does not induce CDC mediated lysis of said cells.

12. The antibody of any one of claims 9-11 wherein said ADCC mediated lysis takes place in the presence of effector cells selected from the group consisting of monocytes, mononuclear cells, NK cells and PMNs.

13. The antibody of any one of claims 9-12 wherein said phagocytosis is by macrophages.

14. The antibody of any one of claims 1-13 which is a monoclonal, chimeric, human or humanized antibody, or a fragment of an antibody.

15. The antibody of any one of claims 1-14 selected from the group consisting of an IgG1, an IgG2, preferably IgG2a and IgG2b, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.

16. The antibody of any one of claims 1-15 wherein GT468 has the amino acid sequence according to SEQ ID NO: 2.

17. The antibody of any one of claims 1-16 wherein the antibody binds specifically to GT468.

18. The antibody of any one of claims 1-17 which binds to native epitopes of GT468 present on the surface of living cells.

19. The antibody of any one of claims 1-18 which is specific for cancer cells, preferably breast cancer cells.

20. The antibody of any one of claims 1-19 wherein said GT468 is expressed on the surface of said cells.

21. The antibody of any one of claims 1-20 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence

selected from the group consisting of SEQ ID NO: 2-10 and 35-79, or an immunogenic fragment or derivative thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment or derivative thereof.

22. An antibody produced by a clone deposited under the accession no. DSM ACC2822 (4E9-1H9), DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2825 (61C11-2B5), DSM ACC2823 (78H11-1H6), DSM ACCXXXX (22-1A-1), DSM ACCXXXX (22-2A-1), DSM ACCXXXX (22-9B-1), DSM ACCXXXX (23-33A-1), DSM ACCXXXX (23-19A-1), DSM ACCXXXX (F11#33F7D12), DSM ACCXXXX (4A12 2D4 1A10), or DSM ACCXXXX (4E9 1D12 2D4).

23. A hybridoma capable of producing the antibody of any one of claims 1 to 22.

24. A hybridoma deposited under the accession no. DSM ACC2822 (4E9-1H9), DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2825 (61C11-2B5), DSM ACC2823 (78H11-1H6), DSM ACCXXXX (22-1A-1), DSM ACCXXXX (22-2A-1), DSM ACCXXXX (22-9B-1), DSM ACCXXXX (23-33A-1), DSM ACCXXXX (23-19A-1), DSM ACCXXXX (F11#33F7D12), DSM ACCXXXX (4A12 2D4 1A10), or DSM ACCXXXX (4E9 1D12 2D4).

25. A conjugate comprising an antibody of any one of claims 1 to 22 coupled to a therapeutic agent.

26. The conjugate of claim 25 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.

27. A pharmaceutical composition comprising an antibody of any one of claims 1 to 22 and/or a conjugate of claim 25 or 26, and a pharmaceutically acceptable carrier.

28. A method of inhibiting growth of a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 22 and/or a conjugate of claim 25 or 26.

29. A method of killing a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 22 and/or a conjugate of claim 25 or 26.

30. A method of inhibiting metastatic spread of a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 22 and/or a conjugate of claim 25 or 26.

31. A method of treating or preventing a disease or disorder involving cells expressing GT468 and/or being characterized by association of GT468 with their cell surface, comprising administering to a subject an antibody of any one of claims 1 to 22, a conjugate of claim 25 or 26 or a pharmaceutical composition of claim 27.

32. The method of claim 31 wherein the disease or disorder is a tumor-related disease.

33. The method of claim 32 wherein the tumor-related disease is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer and hepatocellular cancer.

34. The method of any one of claims 28-33, wherein said GT468 has the amino acid sequence according to SEQ ID NO: 2.

35. The method of any one of claims 28-34 wherein said GT468 is expressed on the surface of said cells.